Navigation Links
Dr Nabil Dib Takes on Special Advisor Role to the Stemedica Board of Directors
Date:1/26/2009

Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).

San Diego, CA (PRWEB) January 26, 2009 -- Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).

"In looking for someone to serve as Special Advisor to the Board, we sought a medical leader who had practical experience in working with the FDA and the research community in advancing therapeutic stem cell solutions. We feel fortunate to have secured an Advisory Relationship with a true leader within the stem cell industry. Dr Nabil Dib has as much extensive research, regulatory and clinical application experience with adult stem therapy as anyone in the United States," said Nikolai Tankovich, MD, PhD, President & Chief Regulatory and Medical Officer of Stemedica.

In accepting the role of Special Advisor, Dr Dib said, "I'm honored to be associated with Stemedica Cell Technologies. As someone who strives to help build this industry, my research tells me that Stemedica stands out as a leader within our sector. Many stem cell research and manufacturing companies make significant progress in the laboratory, but what distinguishes Stemedica is the extent of their clinical research experience."

"With Dr. Dib we get an independent minded, diligent investigator who has the hands on proven experience in advancing stem cell research and technology from bench top to bed side with the highest possible concern for the safety of the patient and the efficacy of the application," said Maynard Howe, PhD, Vice Chairman and CEO for Stemedica.

About Stemedica Technologies, Inc.:
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, Calif.

For more information regarding Stemedica Cell Technologies or the Dr. Nabil Dib appointment, contact Dave McGuigan.

# # #

Read the full story at http://www.prweb.com/releases/2009/01/prweb1907844.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. AARP Disappointed in Senates Inability to Pass Health Care Reform
4. Creating Healing Environments: Healthcare Industrys Largest Sustainability Conference to be Held May 20-22 in Pittsburgh
5. Baxter Releases Ninth Annual Sustainability Report
6. Free will takes flight: how our brains respond to an approaching menace
7. New AHIP Report Takes a Ten Year Look at the Unintended Consequences of State Efforts to Change the Insurance Market
8. Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival
9. Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts
10. Small Town Doctor Takes on Giants in Consumer Healthcare
11. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: